Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target to $64
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Wedbush analyst David Nierengarten maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform and raises the price target from $55 to $64.
Wedbush analyst David Nierengarten maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform and raises the price target from $55 to $64.